{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:53:07Z","timestamp":1776304387711,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pmed.1003515","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000}}],"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>The Systolic Blood Pressure Intervention Trial (SPRINT) showed significant reductions in death and cardiovascular disease (CVD) risk with a systolic blood pressure (SBP) goal of &lt;120 mm Hg compared with a SBP goal of &lt;140 mm Hg. Our study aimed to assess the applicability of SPRINT to Chinese adults. Additionally, we sought to predict the medical and economic implications of this intensive SBP treatment among those meeting SPRINT eligibility.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods and findings<\/jats:title><jats:p>We used nationally representative baseline data from the China Health and Retirement Longitudinal Study (CHARLS) (2011\u20132012) to estimate the prevalence and number of Chinese adults aged 45 years and older who meet SPRINT criteria. A validated microsimulation model was employed to project costs, clinical outcomes, and quality-adjusted life-years (QALYs) among SPRINT-eligible adults, under 2 alternative treatment strategies (SBP goal of &lt;120 mm Hg [intensive treatment] and SBP goal of &lt;140 mm Hg [standard treatment]). Overall, 22.2% met the SPRINT criteria, representing 116.2 (95% CI 107.5 to 124.8) million people in China. Of these, 66.4%, representing 77.2 (95% CI 69.3 to 85.0) million, were not being treated for hypertension, and 22.9%, representing 26.6 (95% CI 22.4 to 30.7) million, had a SBP between 130 and 139 mm Hg, yet were not taking antihypertensive medication. We estimated that over 5 years, compared to standard treatment, intensive treatment would reduce heart failure incidence by 0.84 (95% CI 0.42 to 1.25) million cases, reduce CVD deaths by 2.03 (95% CI 1.44 to 2.63) million cases, and save 3.84 (95% CI 1.53 to 6.34) million life-years. Estimated reductions of 0.069 (95% CI \u22120.28, 0.42) million myocardial infarction cases and 0.36 (95% CI \u22120.10, 0.82) million stroke cases were not statistically significant. Furthermore, over a lifetime, moving from standard to intensive treatment increased the mean QALYs from 9.51 to 9.87 (an increment of 0.38 [95% CI 0.13 to 0.71]), at a cost of Int$10,997 per QALY gained. Of all 1-way sensitivity analyses, high antihypertensive drug cost and lower treatment efficacy for CVD death resulted in the 2 most unfavorable results (Int$25,291 and Int$18,995 per QALY were gained, respectively). Simulation results indicated that intensive treatment could be cost-effective (82.8% probability of being below the willingness-to-pay threshold of Int$16,782 [1\u00d7 GDP per capita in China in 2017]), with a lower probability in people with SBP 130\u2013139 mm Hg (72.9%) but a higher probability among females (91.2%). Main limitations include lack of specific SPRINT eligibility information in the CHARLS survey, uncertainty about the implications of different blood pressure measurement techniques, the use of several sources of data with large reliance on findings from SPPRINT, limited information about the serious adverse event rate, and lack of information and evidence for medication effectiveness on renal disease.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Conclusions<\/jats:title><jats:p>Although adoption of the SPRINT treatment strategy would increase the number of Chinese adults requiring SBP treatment intensification, this approach has the potential to prevent CVD events, to produce gains in life-years, and to be cost-effective under common thresholds.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pmed.1003515","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T19:10:50Z","timestamp":1614885050000},"page":"e1003515","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study"],"prefix":"10.1371","volume":"18","author":[{"given":"Chao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7095-6767","authenticated-orcid":true,"given":"Kangyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0080-1065","authenticated-orcid":true,"given":"Victoria","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-2389","authenticated-orcid":true,"given":"Ewan","family":"Tomeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-2492","authenticated-orcid":true,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8449-7725","authenticated-orcid":true,"given":"Dahai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6712-8602","authenticated-orcid":true,"given":"Zhenqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-2464","authenticated-orcid":true,"given":"Duolao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5489-6450","authenticated-orcid":true,"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"issue":"9882","key":"pmed.1003515.ref001","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0140-6736(13)61097-1","article-title":"Rapid health transition in China, 1990\u20132010: findings from the Global Burden of Disease Study 2010","volume":"381","author":"G Yang","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"pmed.1003515.ref002","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2016.19043","article-title":"Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990\u20132015","volume":"317","author":"MH Forouzanfar","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"pmed.1003515.ref003","doi-asserted-by":"crossref","first-page":"e007462","DOI":"10.1161\/JAHA.117.007462","article-title":"Comparison of prevalence, awareness, treatment, and control of cardiovascular risk factors in China and the United States","volume":"7","author":"Y Lu","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"10112","key":"pmed.1003515.ref004","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/S0140-6736(17)32476-5","article-title":"Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey","volume":"390","author":"M Su","year":"2017","journal-title":"Lancet"},{"issue":"10112","key":"pmed.1003515.ref005","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0140-6736(17)32478-9","article-title":"Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project)","volume":"390","author":"J Lu","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"pmed.1003515.ref006","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.117.032380","article-title":"Status of hypertension in China: results from the China Hypertension Survey, 2012\u20132015","volume":"137","author":"Z Wang","year":"2018","journal-title":"Circulation"},{"key":"pmed.1003515.ref007","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijcard.2016.10.110","article-title":"Burden of hypertension in China: a nationally representative survey of 174,621 adults","volume":"227","author":"Y Li","year":"2017","journal-title":"Int J Cardiol"},{"issue":"22","key":"pmed.1003515.ref008","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SR Group","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"pmed.1003515.ref009","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels\u2014updated overview and meta-analyses of randomized trials","volume":"34","author":"C Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"issue":"7","key":"pmed.1003515.ref010","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","article-title":"Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis","volume":"2","author":"JD Bundy","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"5","key":"pmed.1003515.ref011","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cjca.2016.02.066","article-title":"Hypertension Canada\u2019s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"32","author":"AA Leung","year":"2016","journal-title":"Can J Cardiol"},{"issue":"6","key":"pmed.1003515.ref012","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"PK Whelton","year":"2018","journal-title":"Hypertension"},{"key":"pmed.1003515.ref013","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijcard.2017.05.003","article-title":"Potential health impact and cost-effectiveness of drug therapy for prehypertension","volume":"240","author":"C Tao","year":"2017","journal-title":"Int J Cardiol"},{"key":"pmed.1003515.ref014","doi-asserted-by":"crossref","first-page":"k2357","DOI":"10.1136\/bmj.k2357","article-title":"Impact of 2017 ACC\/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study","volume":"362","author":"R Khera","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"pmed.1003515.ref015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ije\/dys203","article-title":"Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS)","volume":"43","author":"Y Zhao","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"19","key":"pmed.1003515.ref016","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/CIRCULATIONAHA.116.022367","article-title":"Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR Project (Prediction for ASCVD Risk in China)","volume":"134","author":"X Yang","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"pmed.1003515.ref017","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archinte.159.11.1197","article-title":"Profile for estimating risk of heart failure","volume":"159","author":"WB Kannell","year":"1999","journal-title":"Arch Intern Med"},{"key":"pmed.1003515.ref018","unstructured":"World Bank. GDP per capita (current US$). Washington (DC): World Bank; 2019 [cited 2019 May 6]. http:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD."},{"issue":"3","key":"pmed.1003515.ref019","first-page":"182","article-title":"2018 Chinese guidelines for prevention and treatment of hypertension\u2014a report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension","volume":"16","author":"Joint Committee for Guideline Revision","year":"2019","journal-title":"J Geriatr Cardiol"},{"issue":"8","key":"pmed.1003515.ref020","doi-asserted-by":"crossref","first-page":"e1001860","DOI":"10.1371\/journal.pmed.1001860","article-title":"The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study","volume":"12","author":"DF Gu","year":"2015","journal-title":"PLoS Med"},{"issue":"5","key":"pmed.1003515.ref021","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMsa1406751","article-title":"Cost-effectiveness of hypertension therapy according to 2014 guidelines","volume":"372","author":"AE Moran","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"pmed.1003515.ref022","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMsa1616035","article-title":"Cost-effectiveness of intensive versus standard blood-pressure control","volume":"377","author":"AP Bress","year":"2017","journal-title":"N Engl J Med"},{"key":"pmed.1003515.ref023","volume-title":"Generalized cost-effectiveness analysis: a guide","author":"World Health Organization","year":"2003"},{"issue":"5","key":"pmed.1003515.ref024","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2015.10.037","article-title":"Generalizability of SPRINT results to the U.S. adult population","volume":"67","author":"AP Bress","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"pmed.1003515.ref025","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cjca.2018.01.008","article-title":"Applicability of the Systolic Blood Pressure Intervention Trial (SPRINT) to the Canadian population","volume":"34","author":"AA Leung","year":"2018","journal-title":"Can J Cardiol"},{"issue":"17","key":"pmed.1003515.ref026","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1161\/CIRCULATIONAHA.116.025322","article-title":"Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States: projections from NHANES (National Health and Nutrition Examination Survey)","volume":"135","author":"AP Bress","year":"2017","journal-title":"Circulation"},{"issue":"8","key":"pmed.1003515.ref027","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamacardio.2016.3517","article-title":"Cost-effectiveness of intensive blood pressure management","volume":"1","author":"IB Richman","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"1","key":"pmed.1003515.ref028","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/HYPERTENSIONAHA.115.06814","article-title":"Comparative cost-effectiveness of conservative or intensive blood pressure treatment guidelines in adults aged 35\u201374 years: the cardiovascular disease policy model","volume":"68","author":"N Moise","year":"2016","journal-title":"Hypertension"},{"issue":"5","key":"pmed.1003515.ref029","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/HYPERTENSIONAHA.117.10479","article-title":"Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial)","volume":"71","author":"KC Johnson","year":"2018","journal-title":"Hypertension"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1003515","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T02:22:14Z","timestamp":1671502934000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003515","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1003515","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]}}}